18:17 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Clinical holds for Affimed's T cell bispecific following patient death

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Oct. 9 after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The...
20:30 , Oct 9, 2018 |  BC Extra  |  Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product...
18:32 , Sep 28, 2018 |  BioCentury  |  Emerging Company Profile

Stopping chain swapping

By controlling how antibody chains pair, Elstar Therapeutics Inc.’s platform can produce multispecific antibodies at yields comparable to methods for manufacturing monospecific antibodies. The company develops multispecific antibodies with up to four functional domains that...
18:54 , Aug 31, 2018 |  BC Week In Review  |  Company News

Affimed, Genentech in NK cell engager deal

Affimed N.V. (NASDAQ:AFMD) said late Aug. 27 that it partnered with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize NK cell engager-based immunotherapeutics to treat cancers. The news sent Affimed shares...
22:16 , Aug 27, 2018 |  BC Extra  |  Company News

Affimed, Genentech in NK cell engager deal

Affimed N.V. (NASDAQ:AFMD) said late Monday that it partnered with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize NK cell engager-based immunotherapeutics to treat cancers. The news sent Affimed shares up...
21:47 , Mar 19, 2018 |  BC Extra  |  Company News

Management tracks: J&J, Alder, CVS

Johnson & Johnson (NYSE:JNJ) said EVP and CFO Dominic Caruso will retire in September. He is succeeded by VP of investor relations Joseph Wolk. Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) said President and CEO Randall Schatzman will...
00:05 , Feb 17, 2018 |  BC Week In Review  |  Financial News

Affimed raises $26.5M in follow-on

Cancer company Affimed N.V. (NASDAQ:AFMD) raised $26.5 million through the sale of 13.2 million shares at $2 in a follow-on underwritten by Jefferies and Wells Fargo. The figures include the sale of a 1.7 million...
20:50 , Feb 16, 2018 |  BC Week In Review  |  Financial News

Affimed raises $26.5M in follow-on

Cancer company Affimed N.V. (NASDAQ:AFMD) raised $26.5 million through the sale of 13.2 million shares at $2 in a follow-on underwritten by Jefferies and Wells Fargo. The figures include the sale of a 1.7 million...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from three evaluable patients with relapsed or refractory CD30-positive, cutaneous lymphoma in the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13 led to...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from nine evaluable patients with relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13 plus anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co....